Last reviewed · How we verify
Low dose of ritonavir
At a glance
| Generic name | Low dose of ritonavir |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Diarrhoea
- Nausea
- Fatigue
- Headache
- Abdominal Pain Upper
- Vomiting
- Rash
- Dizziness
- Asthenia
- Flatulence
- Decreased Appetite
- Dysgeusia
Key clinical trials
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Lopinavir/Ritonavir in PLWH With High-Grade AIN (PHASE1)
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)
- A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants (PHASE1)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg ("Jonson&Jonson", Russia) (NA)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low dose of ritonavir CI brief — competitive landscape report
- Low dose of ritonavir updates RSS · CI watch RSS
- Boehringer Ingelheim portfolio CI